Legal guides on SGK reimbursement disputes for each of the following targeted cancer drugs: Trastuzumab Deruxtecan, Perjeta, Erbitux, Bevax, Trodelvy, Prexet.
An academic review of the legal avenues available to obtain SGK coverage for trastuzumab deruxtecan (Enhertu) and other off-label targeted cancer therapies in Turkey.
Which HER2-positive breast cancer cases SGK covers for Perjeta (pertuzumab), the legal route for off-label use, and the 2026 price.
The conditions under which SGK covers Erbitux (cetuximab), the legal route when payment is refused, the 2026 price, and required documents.
Which indications SGK covers for Bevax (bevacizumab), the legal process when coverage is refused, and current pricing.
Whether SGK covers Trodelvy, its current 2026 price, the TİTCK approval process, and reclaiming the drug cost through litigation.
Prexet's (pemetrexed disodium) general SGK coverage status, the legal route in case of refusal or delay, required documents, and the 2026 price.
Anonymised official court decisions from 17 SGK drug reimbursement cases we've handled and won.